MOUD Pre-Treatment Telehealth
BehavioralOpioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
NCT Number: NCT04069624
This trial will test the effectiveness of delivering medication for opioid use disorder (MOUD) pre-treatment via telehealth, alone and with peer navigation, to increase MOUD initiation and maintenance in the community following jail release. This trial will focus on incarcerated women in 6 experimental and 3 control sites in Kentucky. Enrollment is not open to the general public.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Hardin County Detention Center, Elizabethtown, Kentucky, United States
This study will incorporate random assignment for two study conditions: medication for opioid use disorder (MOUD) PreTreatment Telehealth or MOUD PreTreatment Telehealth with Peer Navigation using a rigorous randomized block design. Women in the experimental conditions will be stratified by sites (6 sites; 3 urban and 3 non-urban) and by offender classification level of felony versus misdemeanor (due to potential differences in community supervision). Three comparison sites with existing jail-based MOUD treatment for women will not be randomized but will be included in analyses within planned, non-randomized comparisons.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
Medications to treat opioid use disorder (MOUD) pre-treatment.
Time frame: 13 months
Any initiation of MOUD post-release over the study period
Time frame: 13 months
Percentage of participants on naltrexone, buprenorphine or methadone.
Time frame: 13 months
Percentage of participants relapsing, measured by self-report or drug screen.
Time frame: 13 months
Length of time in treatment
Time frame: 12 months
Percent of participants returning to custody
Time frame: 13 months
Percentage of participants who overdose (medical attention needed for revival)
Time frame: 12 months
Percent of participants engaging in criminal activity (self-report or arrest records)
Time frame: 5 years
Total annual intervention cost
Time frame: 13 months
Average intervention cost per participant
Time frame: 5 years
Cost per unit outcome of interventions versus services as usual
Time frame: 5 years
Cumulative estimated cost of hospitalizations, treatments, loss of work, child welfare, and other services related to relapse.
Time frame: 5 years
Cumulative estimated cost of return to custody, arrests, and other social costs of recidivism.
Michele Staton
Other
Acronym: W-JCOIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04632238
Chemically-Induced Disorders, Mental Disorders
Blauvelt, New York, United States
View Trial DetailsNCT04180020
Chemically-Induced Disorders, Mental Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT04808479
Chemically-Induced Disorders, Mental Disorders
Tarzana, California, United States
View Trial DetailsNCT04104022
Chemically-Induced Disorders, Mental Disorders
Burlington, Vermont, United States
View Trial Details